Literature DB >> 32654927

A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.

Siddharth Kunte1, James Stevenson2.   

Abstract

Entities:  

Keywords:  Crizotinib; HLA-DRB1-MET rearrangement; MET fusions; Non–small-cell lung cancer; Targeted treatments

Mesh：

Substances：

Year:  2020        PMID： 32654927     DOI： 10.1016/j.cllc.2020.05.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment.

Authors:  Peng Gao; Kangning Tang; Yuqiu Hao; Wei Li; Xuejiao Lv; Dapeng Li; Yuxi Jia
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

2.  Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report.

Authors:  Lian-Fang Liu; Jia-Ying Deng; Analyn Lizaso; Jing Lin; Si Sun
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

3.  Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin.

Authors:  Chien-Yu Lin; Sheng-Huan Wei; Yi-Lin Chen; Chung-Ta Lee; Shang-Yin Wu; Chung-Liang Ho; Dean C Pavlick; Po-Lan Su; Chien-Chung Lin
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.